Products Affected - Description
There are no affected products
Reason for the Shortage
- American Regent states the reason for the shortage was manufacturing delay.
- Sandoz states the reason for the shortage was increased demand.
Olanzapine Intramuscular Injection, American Regent
10 mg vial (NDC 00517-0955-01)
Olanzapine Intramuscular Injection, Sandoz
10 mg vial (NDC 00781-3159-72)
Zyprexa Intramuscular, Lilly
10 mg vial (NDC 00002-7597-01)
Estimated Resupply Dates
All presentations are available.
December 16, 2014; December 2, 2014; November 14, 2014; October 21, 2014; October 10, 2014; September 3, 2014; August 19, 2014; June 19, 2014; May 15, 2014; April 16, 2014, University of Utah, Drug Information Service. Copyright 2014, Drug Information Service, University of Utah, Salt Lake City, UT.
This information is provided through the support of Novation to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Novation, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Novation, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Novation, ASHP nor University of Utah endorses or recommends the use of any drug.
« Back to Drug Shortage Product Bulletins